TRVI - NASDAQ

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

TRVIยทNASDAQ

$13.45

-3.6%
HealthcareBiotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.91B
EPS-0.2900
P/E Ratio-46.38
Earnings Date08/06/2026
Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. Fair Value Envelope

TRVI ยท NASDAQ

Our analysis suggests that TRVI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.45, this represents a potential HIDDEN relative to our calculated worth for Trevi Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $13.45

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$176.9M
+ Cash & Equivalents$18.9M
Firm Value-$158.0M
- Debt$753.0K
Equity Value-$158.7M
/ Shares Outstanding121,776,855B
DCF Value-$1
OVERVALUED BY 110%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$37.9M
-$34.1M
-$30.7M
-$27.7M
-$24.9M
-$22.4M
-$20.2M
-$18.2M
-$16.4M
-$14.8M
Maintenance CapEx
-$2.2K
-$1.9K
-$1.8K
-$1.6K
-$1.4K
-$1.3K
-$1.2K
-$1.0K
-$934
-$841
Owner Earnings
-$37.9M
-$34.1M
-$30.7M
-$27.7M
-$24.9M
-$22.4M
-$20.2M
-$18.2M
-$16.4M
-$14.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$35.1M
-$29.3M
-$24.4M
-$20.3M
-$17.0M
-$14.1M
-$11.8M
-$9.8M
-$8.2M
-$6.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TRVI research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.